Adaptive Biotechnologies to Split MRD and Immune Medicine Businesses

What happened

Adaptive Biotechnologies announced plans to separate its MRD and Immune Medicine businesses, sending shares higher. The move sharpens the company's focus on its core MRD diagnostics franchise, which is the centerpiece of the DeepValue BUY thesis. The Immune Medicine segment, which includes the soon-to-be-terminated Genentech collaboration and has been a revenue drag, will be isolated. While the split could unlock shareholder value and improve capital allocation transparency, it also introduces execution risk and potential distraction. The timing aligns with management's renewed emphasis on achieving MRD profitability in 2025 and reducing cash burn.

Implication

If Adaptive successfully executes the separation and the MRD business continues to gain reimbursement and volume traction, the stock could re-rate higher. However, if the Immune Medicine unit becomes a value-destructive overhang or the split distracts from MRD growth, the thesis weakens.

Thesis delta

The split confirms Adaptive's strategic pivot to MRD diagnostics as the primary value driver, consistent with our prior stance. However, it introduces operational complexity and potential near-term costs that could delay the path to profitability. We maintain a BUY but with heightened focus on execution milestones.